Janney Montgomery Scott LLC Has $554,000 Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Janney Montgomery Scott LLC reduced its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 44.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 29,395 shares of the company's stock after selling 23,313 shares during the quarter. Janney Montgomery Scott LLC owned 0.06% of Pacira BioSciences worth $554,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in PCRX. Pacer Advisors Inc. boosted its stake in shares of Pacira BioSciences by 129.4% during the 3rd quarter. Pacer Advisors Inc. now owns 4,962,221 shares of the company's stock worth $74,681,000 after acquiring an additional 2,799,434 shares in the last quarter. BNP Paribas Financial Markets boosted its position in Pacira BioSciences by 269.7% during the third quarter. BNP Paribas Financial Markets now owns 395,695 shares of the company's stock valued at $5,955,000 after purchasing an additional 288,662 shares during the last quarter. Empowered Funds LLC acquired a new stake in Pacira BioSciences during the third quarter valued at $3,286,000. Verition Fund Management LLC acquired a new stake in Pacira BioSciences during the third quarter valued at $493,000. Finally, Segall Bryant & Hamill LLC bought a new position in Pacira BioSciences during the third quarter valued at about $483,000. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Pacira BioSciences Trading Down 0.4 %

Shares of Pacira BioSciences stock traded down $0.12 on Wednesday, hitting $27.13. 457,942 shares of the company's stock traded hands, compared to its average volume of 842,595. The firm's 50-day moving average price is $21.56 and its two-hundred day moving average price is $18.00. The stock has a market capitalization of $1.25 billion, a PE ratio of -13.36 and a beta of 0.80. Pacira BioSciences, Inc. has a one year low of $11.16 and a one year high of $31.67. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89.

Analysts Set New Price Targets

Several research firms have weighed in on PCRX. Truist Financial upgraded Pacira BioSciences from a "sell" rating to a "hold" rating and raised their target price for the company from $8.00 to $25.00 in a report on Thursday, January 30th. HC Wainwright restated a "buy" rating and set a $39.00 price target on shares of Pacira BioSciences in a research note on Wednesday, December 4th. Barclays decreased their price objective on Pacira BioSciences from $25.00 to $17.00 and set an "equal weight" rating on the stock in a report on Tuesday, November 12th. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $18.00 price objective on shares of Pacira BioSciences in a report on Tuesday, January 14th. Finally, Needham & Company LLC boosted their target price on Pacira BioSciences from $22.00 to $30.00 and gave the stock a "buy" rating in a report on Monday, January 13th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $22.78.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.